Denali Therapeutics (DNLI) EPS (Weighted Average and Diluted) (2018 - 2026)
Denali Therapeutics (DNLI) reported EPS (Weighted Average and Diluted) of -$0.69 for Q1 2026, up 11.54% year-over-year from -$0.62 in Q1 2025, and up 5.48% quarter-over-quarter from -$0.73 in Q4 2025.
Denali Therapeutics (DNLI) EPS (Weighted Average and Diluted) (2018 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has 9 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.69 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.69, up 11.54% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.88 (down 7.46% YoY), and the FY2025 annual result was -$2.97, down 15.56% from the prior year.
- EPS (Weighted Average and Diluted) advanced to -$0.69 in Q1 2026 per DNLI's latest filing, from -$0.73 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $1.3 in Q2 2023 and troughed at -$0.87 in Q4 2023.
- A 5-year average of -$0.58 and a median of -$0.72 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) jumped 370.83% in 2023, then sank 145.38% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.75 in 2022, then declined by 16.0% to -$0.87 in 2023, then increased by 21.84% to -$0.68 in 2024, then declined by 7.35% to -$0.73 in 2025, then climbed by 5.48% to -$0.69 in 2026.
- Business Quant data shows DNLI's EPS (Weighted Average and Diluted) at -$0.69 in Q1 2026, -$0.73 in Q4 2025, and -$0.74 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - | -0.69 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.69 |
| Dec 31, 2025 | -0.73 |
| Sep 30, 2025 | -0.74 |
| Jun 30, 2025 | -0.72 |
| Mar 31, 2025 | -0.78 |
| Dec 31, 2024 | -0.68 |
| Sep 30, 2024 | -0.63 |
| Jun 30, 2024 | -0.59 |
| Mar 31, 2024 | -0.68 |
| Dec 31, 2023 | -0.87 |
| Sep 30, 2023 | -0.72 |
| Jun 30, 2023 | 1.30 |
| Mar 31, 2023 | -0.80 |
| Dec 31, 2022 | -0.75 |
| Sep 30, 2022 | -0.84 |
| Jun 30, 2022 | -0.48 |
| Mar 31, 2022 | -0.53 |
| Dec 31, 2021 | -0.62 |
| Sep 30, 2021 | -0.69 |
| Jun 30, 2021 | -0.50 |